Theratechnologies' Pending Sale to Future Pak

Cleary Gottlieb is representing Barclays Capital Inc. as financial advisor to Theratechnologies Inc. (Theratechnologies) in its pending sale to CB Biotechnology, an affiliate of Future Pak, for approximately $254 million.

The transaction was announced on July 2, 2025, and is anticipated to close late in the fourth quarter of 2025, pending customary regulatory approvals and closing conditions.

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a Canada-based specialty biopharmaceutical company focused on the commercialization of innovative therapies. Theratechnologies partners with academic institutions and industry organizations to bring advanced therapeutic products to the market, leveraging its expertise in clinical science and regulatory processes.

Future Pak, along with its affiliates, is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products headquartered in Michigan. Future Pak operates across retail, specialty, and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.

For more information, please see the press release.